Zacks Investment Research downgraded shares of RTI BIOLOGICS (RTIX) from OUTPERFORM to NEUTRAL on June 27, 2012, with a target price of $4.20.
RTI BIOLOGICS, Inc. prepares human donated tissue and bovine tissue for transplantation with a commitment to advancing science, safety and innovation. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries. RTI's innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on RTI BIOLOGICS (RTIX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment